Updates on Metabolic Dysfunction-Associated Steatohepatitis Treatment

Two FDA-approved MASH therapies are changing care. Learn how resmetirom and semaglutide work—and what's next in the pipeline.

Credit available for this activity expires: 6/18/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/updates-metabolic-dysfunction-associated-steatohepatitis-2026a1000jmw?ecd=bdc_podcast_libsyn_mscpedu